Jeffrey S. Ross

SUNY Upstate Medical University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

70h-index35.2kcitations965works9.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(99), Spine and Intervertebral Disc Pathology(98), Laser-Plasma Interactions and Diagnostics(60), Glioma Diagnosis and Treatment(47), Advanced MRI Techniques and Applications(47)

Publications960 total

Fanconi anemia complementation group C gene (FANCC) association with hereditary and sporadic renal tumors
The Oncologist·2026Open Access
Inferring optimal detection of <i>MTAP</i> homozygous loss (homozygous deletion) in pancreatic cancer: Association with treatment exposure, co-alterations, site of biopsy, and clinical outcomes.
Journal of Clinical Oncology·2026
Neuroendocrine carcinoma of the esophagus: A genomic landscape study.
Journal of Clinical Oncology·2026
<i>ERBB3</i> driver genomic alterations in intrahepatic cholangiocarcinoma: A genomic landscape and clinical outcome study.
Journal of Clinical Oncology·2026
Clinical determinants of survival and a predictive immune biomarker for immunotherapy in fibrolamellar carcinoma: A comprehensive institutional analysis.
Journal of Clinical Oncology·2026
TP53 Y220C mutation in esophageal adenocarcinoma: A genomic landscape study.
Journal of Clinical Oncology·2026
MTAP loss in anal melanoma: A genomic landscape study.
Journal of Clinical Oncology·2026
Spontaneous refractive error, ocular biometry and age related lens changes in a population of geriatric rhesus macaques
Scientific Reports·2025Open Access
Coverage of actionable alterations in non-small cell lung cancer by hybrid capture-based FoundationOne®CDx compared with amplicon-based OncomineDX
The Oncologist·2025· 1 citedOpen Access
Tumor Mutational Burden (TMB) predicts the outcome of patients (pts) with Muscle-Invasive Bladder Cancer (MIBC) undergoing Immune-Checkpoint Inhibitor (ICI)-based neoadjuvant therapy
European Urology Open Science·2025Open Access
Myoepithelial and epithelial-myoepithelial clinically advanced and metastatic carcinomas of salivary gland: A comparative comprehensive genomic profiling study
Human Pathology·2025
157P Homologous recombination signature (HRDsig) in non-small cell lung cancer (NSCLC): Implications for PARP inhibitor (PARPi) treatment
Annals of Oncology·2025
2150P Homologous recombination deficiency signature in gastric adenocarcinoma
Annals of Oncology·2025
Homozygous loss of homologous repair genes and durable benefit from poly (ADP-ribose) polymerase inhibitors maintenance for patients with ovarian cancer
Gynecologic Oncology·2025
Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study
ESMO Open·2025· 2 citedOpen Access
Homologous recombination deficiency signature (HRDsig) in advanced cutaneous melanoma (ACM): A genomic landscape study.
Journal of Clinical Oncology·2025
Pancreatic adenosquamous carcinoma (PASC): A comparative genomic landscape study.
Journal of Clinical Oncology·2025
Comparison of <i>MET</i> genomic alterations (GA) identified in colorectal cancer (CRC) vs gastric cancer (GCA).
Journal of Clinical Oncology·2025
Spontaneous Refractive Error, Ocular Biometry and Age Related Lens Changes in a Population of Geriatric Rhesus Macaques
2025Open Access
Homologous recombination deficiency signature (HRDsig+) and the genomic landscape of clinically advanced prostate carcinoma (CAPC).
Journal of Clinical Oncology·2025
page 1 of 48Next →

Frequent Co-authors

Michael T. Modic(15), Thomas J. Masaryk(11), Nancy A. Obuchowski(10), S. H. Glenzer(6), L. Divol(5), Henry H. Bohlman(5), Michael Brant‐Zawadzki(4), J. E. Ralph(4), Michael T. Modic(4), E. Mark Haacke(4), Warren R. Selman(4), M T Modic(4), T J Masaryk(4), O. A. Hurricane(3), D. A. Callahan(3), D. T. Casey(3), S. Le Pape(3), A. Pak(3), L. Berzak Hopkins(3), S. D. Bhandarkar(3)